MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc., a public company registered with the SEC and developer of therapeutics and dietary supplements that target diabetes and pre-diabetes today announced that it closed a private placement yielding gross proceeds to the Company of $508,000. Boston Therapeutics sold 2,032,000 shares of its common stock at a purchase price of $0.25 per share. Boston Therapeutics, Inc. intends to use the proceeds from its offering primarily for working capital, clinical trials and general administration.
